Vcanbio Cell & Gene Engineering Corp., Ltd

XSSC:600645 Stock Report

Market Cap: CN¥9.3b

Vcanbio Cell & Gene Engineering Past Earnings Performance

Past criteria checks 2/6

Vcanbio Cell & Gene Engineering has been growing earnings at an average annual rate of 37.6%, while the Biotechs industry saw earnings growing at 7.6% annually. Revenues have been growing at an average rate of 4.1% per year. Vcanbio Cell & Gene Engineering's return on equity is 2.8%, and it has net margins of 6.7%.

Key information

37.6%

Earnings growth rate

38.3%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate4.1%
Return on equity2.8%
Net Margin6.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Vcanbio Cell & Gene Engineering makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSSC:600645 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,593107732201
30 Jun 241,594109731200
31 Mar 241,610109742193
31 Dec 231,590106744183
30 Sep 231,581131724154
30 Jun 231,584131739154
31 Mar 231,538115734150
31 Dec 221,555113738146
30 Sep 221,55279794141
30 Jun 221,536109793128
31 Mar 221,563146793133
31 Dec 211,535155787134
30 Sep 211,509-69753121
30 Jun 211,467-97715127
31 Mar 211,409-87687114
31 Dec 201,319-127647112
30 Sep 201,35189618125
30 Jun 201,33868624113
31 Mar 201,34225633112
31 Dec 191,38750635108
30 Sep 191,355-182676115
30 Jun 191,345-189692109
31 Mar 191,320-43693103
31 Dec 181,32159707101
30 Sep 181,33331767684
30 Jun 181,32732265291
31 Mar 181,434116703124
31 Dec 171,32110673102
30 Sep 171,2386062980
30 Jun 171,1132257952
31 Mar 17876724610
31 Dec 16838384230
30 Sep 167681303750
30 Jun 16740-643620
31 Mar 16721413510
31 Dec 157092083530
30 Sep 15676693600
30 Jun 156153053400
31 Mar 155441883070
31 Dec 14477352870
30 Sep 14400572470
30 Jun 14389292380
31 Mar 14383232460
31 Dec 1336172420

Quality Earnings: 600645 has high quality earnings.

Growing Profit Margin: 600645's current net profit margins (6.7%) are lower than last year (8.3%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 600645 has become profitable over the past 5 years, growing earnings by 37.6% per year.

Accelerating Growth: 600645's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 600645 had negative earnings growth (-17.9%) over the past year, making it difficult to compare to the Biotechs industry average (1.3%).

Return on Equity

High ROE: 600645's Return on Equity (2.8%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 14:55
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vcanbio Cell & Gene Engineering Corp., Ltd is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bin WuFounder Securities Co., Ltd.
Ye Hui YangHuatai Research
Ban WangMinsheng Securities Co.